Original Papers 931
chromatography and eluted with chloroform-methanol-water
(10:3:0.5, v/v/v) to obtain compound 10 (22.2 mg).
Table 1 1H and 13C‑NMR chemical shift assignments for the aglycone moiety
of compounds 8 and 10 in C5D5N.
Compound 8: colorless, amorphous powder; [α]2D3 − 50.0 (c 0.10;
8
10
MeOH); IR (film) νmax 3410, 2925, 1700, 1645, 1374, 1042 cm−1
;
1H NMR (C5D5N, 500 MHz) and 13C NMR (C5D5N, 125 MHz) as-
Position
δC
δH
δC
δH
"
1
2
36.7
29.8
77.3
34.7
44.6
28.7
31.5
34.4
55.7
36.4
38.1
0.69, 1.30
1.55, 1.97
3.89
37.2
30.0
77.5
34.9
44.7
29.0
32.5
35.3
54.5
35.9
21.3
0.77, 1.49
1.61, 2.04
3.93
signments (l Tables 1 and 2); ESI‑MS (neg. ion mode) m/z
1325.4 [M – H]−, 1193.6, 1031.5, 885.5, 753.5, 591.4, HR FAB‑MS
(pos. ion mode) m/z 1349.5981 [M + Na]+, (calcd. for C61H98O31Na,
1349.5990).
3
4
1.22, 1.76
0.84
1.33, 1.77
0.87
5
Compound 10: colorless, amorphous powder; [α]2D3 − 63.0 (c 0.10;
6
1.11
1.03, 1.10
0.77, 1.50
1.38
MeOH); IR (film) νmax 3449, 2928, 1631, 1062 cm−1 1H NMR
;
7
1.56, 2.10
1.76
(C5D5N, 500 MHz) and 13C NMR (C5D5N, 125 MHz) assignments
8
−
"
(l Tables 1 and 2); ESI‑MS (neg. ion mode) m/z 1341.4 [M – H] ,
1209.6, 1047.6, 901.5, 739.5, 577.4, HR FAB‑MS (pos. ion mode)
m/z 1365.6293 [M + Na]+ (calcd. for C62H102O31Na, 1365.6303).
9
0.88
0.48, t, J = 10.7
10
11
2.21, brd, J = 13.6
2.36, t, J = 13.6
1.19, 1.38
1.01, 1.64
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
213.2
55.5
56.0
31.9
79.8
54.4
16.2
11.8
42.7
14.0
109.5
31.8
29.3
30.7
67.1
40.2
40.8
56.5
32.2
81.3
62.9
16.7
12.4
42.5
15.0
109.8
26.4
26.3
27.6
65.2
Acid hydrolysis and sugar analysis
Compounds 8 and 10 (2.0 mg each) were hydrolyzed with 4 N
aqueous HCl (0.5 mL) at 60°C for 1 h. The reaction mixture was
partitioned between ethyl acetate and water. The water layer
was neutralized by passing it through an ion exchange solid
phase extraction (SPE) cartridge (Strata X‑AW 33 µm polymeric
Weak Anion; Phenomenex) [8]. After removal of the solvent
under reduced pressure, the evaporation residue of the aqueous
layer was dissolved in anhydrous pyridine (1 mL), and L-cysteine
methyl ester hydrochloride (2.3 mg) was added. The mixture was
stirred at room temperature for 24 h. Then 300 µL of HMDS-TMCS
(hexamethyldisilazane-trimethylchlorosilane, 2:1) was added,
and the mixture was stirred at room temperature for 30 min.
The precipitate was centrifuged off, and 20 µL of supernatant
was added into ethyl acetate (950 µL). After being well mixed
and filtered, the solution was analyzed by GC‑FID [9]. The pro-
gram of oven temperature was 180 to 300°C at 4°C/min; injec-
tion temperature 250°C; the carrier had a heat flow rate of
0.8 mL/min. The silylated standards of D-galactose, D-glucose,
D-xylose, and L-rhamnose were detected at 19.75, 19.32, 15.27,
and 16.56 min, respectively. Identification of D-galactose, D-glu-
cose, D-xylose, and L-rhamnose was carried out for compounds 8
and 10, giving peaks respectively at 19.76, 19.32, 15.27, and
16.56 min for compound 8, and at 19.80, 19.36, 15.32, and
16.60 min for compound 10.
1.34
1.00
0.75, 1.56
4.47
1.38, 2.00
4.50
2.74, t, J = 7.4
1.07, s
1.77
0.80, s
0.63, s
1.88
0.65, s
1.91, t, J = 6.7
1.33, d, J = 6.7
1.13, d, J = 6.7
1.60, 1.70
1.56
1.44, 1.89
1.34, 2.12
1.57
1.56
3.47, 3.59
3.35, d, J = 10.8
4.06
27
17.5
0.68, d, J = 5.4
16.4
1.06, d, J = 7.1
number data as percentage of control versus compound concen-
tration, and the IC50 was the point on the graph where 50%
growth inhibition occurred. Each data point represented the
mean of at least 3 independent experiments run in triplicate
[10]. Actinomycin D (98%, Sigma) was used as the positive con-
trol. The purity of the test samples was greater than 95% as veri-
fied by HPLC and NMR.
Growth inhibition assay
Supporting information
Human MCF-7 breast cancer and NCI-H460 non-small cell lung
cancer cell lines were purchased from the American Type Culture
Collection (ATCC). Human SF-268 glioblastoma cell line was pur-
chased from the National Cancer Institute (NCI). These three cell
lines were maintained in Dulbeccoʼs modified Eagleʼs medium
supplemented with 10% fetal calf serum and nonessential amino
acids (Life Technologies, Inc.) at 37°C in a humidified incubator
with 5% CO2 and utilized by the Developmental Therapeutics
Program of the NCI for anticancer compound prescreen. Cells in
logarithmic growth phase were cultured at a density of 10000
cells·mL−1 in a 24-well plate. The cells were treated with various
concentrations of compounds 1–10 for 72 h. Subsequently, the
cells were fixed and stained with 50% ethanol containing 0.5%
methylene blue for 30 min. The plates were washed 5 times with
water and then air-dried. The resulting residue was dissolved in
1% N-lauroyl-sarcosine, and then the optical density was mea-
sured at 570 nm using a microplate reader. Cell number data
were normalized to the percentage of vehicle-treated control
and then graphed. IC50 values were determined by graphing cell
1H, 13C NMR, and selective TOCSY spectra of compounds 8 and 10
are available as Supporting Information.
Results and Discussion
!
Chromatographic fractionation of a methanolic extract of A. sisa-
lana leaves yielded 2 new compounds, 8 and 10 (l Fig. 1), and
"
8 known compounds, 1–7 and 9. The structures of the com-
pounds were identified by using spectroscopic analysis, 2D NMR,
and acid hydrolysis. Compounds 1–7 and 9 were identified by
comparing their spectroscopic data with published results for
tigogenin (1) [11], neotigogenin (2) [11], hecogenin (3) [12], neo-
hecogenin (4) [13], rockogenin (5) [14], cantalasaponin-1 (6)
[15], hecogenin 3-O-β-D-glucopyranosyl-(1→2)-[β-D-xylo-
pyranosyl-(1→3)]-β-D-glucopyranosyl-(1→4)-β-D-galactopyra-
noside (7) [7], and polianthosides E (9) [16].
Compound 8 was obtained as a colorless amorphous powder. Its
molecular formula was assigned as C61H98O31 on the basis of the
Chen P-Y et al. Cytotoxic Steroidal Saponins… Planta Med 2011; 77: 929–933